A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations
Acute myeloid leukaemia (AML) with FLT3 mutation has a dismal prognosis in elderly patients. Treatment with a combination of FLT3 inhibitors and standard chemotherapy has not been extensively studied. Therefore, we instigated a phase I/II clinical trial of chemotherapy with cytosine arabinoside (Ara...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
29 March 2015
|
| In: |
British journal of haematology
Year: 2015, Jahrgang: 169, Heft: 5, Pages: 694-700 |
| ISSN: | 1365-2141 |
| DOI: | 10.1111/bjh.13353 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1111/bjh.13353 Verlag, Volltext: http://onlinelibrary.wiley.com/doi/10.1111/bjh.13353/abstract 
|
| Verfasserangaben: | Walter Fiedler, Sabine Kayser, Maxim Kebenko, Melanie Janning, Jürgen Krauter, Marcus Schittenhelm, Katharina Götze, Daniela Weber, Gudrun Göhring, Veronica Teleanu, Felicitas Thol, Michael Heuser, Konstanze Döhner, Arnold Ganser, Hartmut Döhner and Richard F. Schlenk |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1557718997 | ||
| 003 | DE-627 | ||
| 005 | 20240316100203.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170502s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.13353 |2 doi | |
| 035 | |a (DE-627)1557718997 | ||
| 035 | |a (DE-576)487718992 | ||
| 035 | |a (DE-599)BSZ487718992 | ||
| 035 | |a (OCoLC)1340973274 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Fiedler, Walter |e VerfasserIn |0 (DE-588)1027578748 |0 (DE-627)729427226 |0 (DE-576)373414943 |4 aut | |
| 245 | 1 | 2 | |a A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations |c Walter Fiedler, Sabine Kayser, Maxim Kebenko, Melanie Janning, Jürgen Krauter, Marcus Schittenhelm, Katharina Götze, Daniela Weber, Gudrun Göhring, Veronica Teleanu, Felicitas Thol, Michael Heuser, Konstanze Döhner, Arnold Ganser, Hartmut Döhner and Richard F. Schlenk |
| 264 | 1 | |c 29 March 2015 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.05.2017 | ||
| 520 | |a Acute myeloid leukaemia (AML) with FLT3 mutation has a dismal prognosis in elderly patients. Treatment with a combination of FLT3 inhibitors and standard chemotherapy has not been extensively studied. Therefore, we instigated a phase I/II clinical trial of chemotherapy with cytosine arabinoside (Ara-C)/daunorubicin induction (7+3) followed by three cycles of intermediate-dose Ara-C consolidation in 22 AML patients with activating FLT3 mutations. Sunitinib was added at predefined dose levels and as maintenance therapy for 2 years. At dose level 1, sunitinib 25 mg daily continuously from day 1 onwards resulted in two cases with dose-limiting toxicity (DLT), prolonged haemotoxicity and hand-foot syndrome. At dose level −1, sunitinib 25 mg was restricted to days 1-7 of each chemotherapy cycle. One DLT was observed in six evaluable patients. Six additional patients were treated in an extension phase. Thirteen of 22 patients (59%; 8/14 with FLT3-internal tandem duplication and 5/8 with FLT3-tyrosine kinase domain) achieved a complete remission/complete remission with incomplete blood count recovery. For the 17 patients included at the lower dose level, median overall, relapse-free and event-free survival were 1·6, 1·0 and 0·4 years, respectively. Four out of five analysed patients with relapse during maintenance therapy lost their initial FLT3 mutation, suggesting outgrowth of FLT3 wild-type subclones. | ||
| 650 | 4 | |a acute myeloid leukaemia | |
| 650 | 4 | |a elderly patients | |
| 650 | 4 | |a FLT3 mutation | |
| 650 | 4 | |a phase I/II study | |
| 650 | 4 | |a sunitinib | |
| 700 | 1 | |a Kayser, Sabine |d 1979- |e VerfasserIn |0 (DE-588)138694923 |0 (DE-627)605256233 |0 (DE-576)30778813X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d Oxford [u.a.] : Wiley-Blackwell, 1955 |g 169(2015), 5, Seite 694-700 |h Online-Ressource |w (DE-627)269758941 |w (DE-600)1475751-5 |w (DE-576)09113997X |x 1365-2141 |7 nnas |a A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations |
| 773 | 1 | 8 | |g volume:169 |g year:2015 |g number:5 |g pages:694-700 |g extent:7 |a A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.13353 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://onlinelibrary.wiley.com/doi/10.1111/bjh.13353/abstract |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20170502 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 138694923 |a Kayser, Sabine |m 138694923:Kayser, Sabine |d 910000 |d 910100 |e 910000PK138694923 |e 910100PK138694923 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 999 | |a KXP-PPN1557718997 |e 2968244264 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"title":[{"title_sort":"phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations","title":"A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations"}],"relHost":[{"id":{"eki":["269758941"],"doi":["10.1111/(ISSN)1365-2141"],"zdb":["1475751-5"],"issn":["1365-2141"]},"recId":"269758941","name":{"displayForm":["ed. R. B. Thompson [u.a.]"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 08.05.08"],"pubHistory":["1.1955 -"],"disp":"A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutationsBritish journal of haematology","part":{"text":"169(2015), 5, Seite 694-700","volume":"169","extent":"7","pages":"694-700","year":"2015","issue":"5"},"language":["eng"],"titleAlt":[{"title":"the official journal of the British Society of Haematology"},{"title":"BJH ; the official journal of the British Society for Haematology"}],"title":[{"subtitle":"BJHaem : an official journal of the British Society for Haematology","title_sort":"British journal of haematology","title":"British journal of haematology"}],"origin":[{"dateIssuedDisp":"1955-","dateIssuedKey":"1955","publisherPlace":"Oxford [u.a.] ; Oxford ; Oxford [u.a.]","publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"corporate":[{"roleDisplay":"Herausgebendes Organ","display":"British Society for Haematology","role":"isb"},{"roleDisplay":"Herausgebendes Organ","role":"isb","display":"European Hematology Association"}]}],"origin":[{"dateIssuedDisp":"29 March 2015","dateIssuedKey":"2015"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1557718997"],"doi":["10.1111/bjh.13353"]},"recId":"1557718997","name":{"displayForm":["Walter Fiedler, Sabine Kayser, Maxim Kebenko, Melanie Janning, Jürgen Krauter, Marcus Schittenhelm, Katharina Götze, Daniela Weber, Gudrun Göhring, Veronica Teleanu, Felicitas Thol, Michael Heuser, Konstanze Döhner, Arnold Ganser, Hartmut Döhner and Richard F. Schlenk"]},"person":[{"family":"Fiedler","given":"Walter","role":"aut","display":"Fiedler, Walter","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Kayser, Sabine","role":"aut","given":"Sabine","family":"Kayser"}],"physDesc":[{"extent":"7 S."}],"note":["Gesehen am 02.05.2017"]} | ||
| SRT | |a FIEDLERWALPHASEIIIST2920 | ||